The Patients’ Access to Treatment Act (HR 1600) states that an insurance company cannot charge more for a drug that they place on a specialty tier than they charge for drugs placed on their non-preferred brand tier.
HFA is a member of the Coalition for Accessible Treatments, a coalition of patient advocacy groups that work together to help pass the Patients’ Access to Treatment Act.
|HFA Issue Brief on Specialty Tiers
(Updated for 2016)
|More information about H.R. 1600, the Patients’ Access to Treatment Act|
|Milliman Report, Specialty Tiers: Benefit Design Considerations for Medicare Part D
This study performed by Milliman examines the use of specialty tiers in Medicare Part D plans.
|Avalere Health Study
The Avalere Health Study examines the impact of HR 460\, the Patient’s Access to Treatment Act.